Most patients begin to see weight loss after their dose has been increased one to two times, typically within a month
Retatrutide has produced an average weight loss of 28.7%, compared to 20.7% with Wegovys newer 7.2 mg dose and 14.9% with the 2.4 mg dose
Men with high-risk cardiac conditions (recent stroke, unstable angina, severe heart failure, etc.) are generally advised to avoid PT-141
Its thiol side chain often participates in enzymatic reactions, and contributes to the stability of proteins by forming disulfide bonds
Preclinical work demonstrates incretin receptor gene and protein expression in female reproductive tissues such as ovary and uterine structures in animal models, supporting the concept that incretin signalling can interact with reproductive physiologyagain, not equivalent to a clinically meaningful direct vaginal mucosal effect in humans
dropping rapamycin (a drug many people take for potential longevity benefits), which he stopped in 2024